Bristol-Myers Squibb Co. (NYSE:BMY)
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Solid dividend payer should outperform over time.
Recs
One of the best pipelines if not the best,with great PE/Yield #'s
Recs
Good numbers, good payout ratio, good debt, good cash on hand, good pipeline, good diversity of drugs, and good dividend. Probably make this one 2%.
Recs
Valuation, patent cliff this year
Recs
Recs
product line & mgm't innovations
Recs
a strong pharma company with a good pipeline
Recs
Buybacks and solid pipeline means price growth, or at least better performance than the S&P 500.
Recs
Hillary says so.
Recs
Nice dividend.
Strong drug portfolio and healthy pipeline.
Cut operating costs, more cuts planned, and new drugs planned for release expected to offset patent losses in 2012-2015.
Recs
Nice dividend return...
Recs
By Reader Request: Here's What to Buy If You're Opportunistic … but Still Scared - TMF staff
Recs
Bristol Myers is an undervalued company poised for even more growth and stability, as well as a solid dividend. The P/E is around 13, just about my benchmark, and the P/S is 2.5. Year over year we have seen a growth of 32.56% in EPS and enough cash to cover their dividend and grow that too or the company more.
Recs
QUALITY STOCK, NEW PRODUCT INTRODUCED, AND NICE DIVIDEND.
Recs
BMY is in a solid business position. Their drug portfolio is wide-ranging and covers cardiovascular, HIV, cancer, and neuropathy. Their products (such as Plavix and Abilify) are well accepted by the Health Care industry and prescribed regularly. Looking forward, a new cancer drug was just approved in Europe, and many more drugs are in trials, including more promising cancer treatments.
Recs
Low debt/equity, very innovative pipeline pushed down over long time for previous malfeasance, also an attractive takeover target when legal issues finish
Recs
Low debt/equity, at 0.35. Reasonable price/earnings, at 14.95, which is low for historic levels of BMY. Market cap of 45.56 billion leaves some room to grow, but also indicates stability. However, the most single impressive track record of BMY is its historic positive and impressive values for Return on Invested Capital.
Recs
Ok I like the dividend I like a few of their products... and TrackJimCramer gives it a Red thumb. So you know it's on its way UP!!!
Recs
Pharmacy may have strong support this year in case of Japan catastrophe
Recs
value,growth,safety,innovation.......
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 233 : 1 2 3 4 5 6 7 8 9 10 Next »